SEC Filings

8-K
AVEXIS, INC. filed this Form 8-K on 06/07/2017
Entire Document
 

 

Item 8.01                                           Other Events.

 

On June 7, 2017, the Company issued a press release announcing the REGENX License.  The full text of the Company’s press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

 

Item 9.01.                                        Financial Statements and Exhibits.

 

(d) Exhibits

 

Exhibit

 

 

Number

 

Exhibit Description

99.1

 

Press Release, dated June 7, 2017, titled “AveXis and REGENXBIO Announce New Exclusive Worldwide Licenses for the Treatment of Two Rare Neurological Monogenic Disorders Using NAV AAV9 Vector.”

 

3



© AveXis, Inc. All Rights Reserved.